Parkinson’s Breakthrough: Blocking Disease Spread at the Source
Key discovery: Researchers found that a cell surface protein called Aplp1 helps spread harmful material linked to Parkinson’s from one brain cell to another
Critical interaction: Aplp1 works alongside another protein, LAG-3, to enable this damaging process
Unexpected solution: An FDA-approved cancer drug that targets LAG-3 was able to block this spread in mice
Disease control potential: Interrupting the Aplp1–LAG-3 interaction may slow or even halt disease progression
Big implication: A potential therapy may already exist—repurposing an existing drug could accelerate treatment development
Bottom line: Targeting how Parkinson’s spreads in the brain—not just its symptoms—could redefine future treatments.For Free Tips Visit Here: 
Disclaimer: These findings are based on preclinical studies. Human trials are needed to confirm safety and effectiveness.
